Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients

WellnessLeave a comment

IMAGE: Abstract O-026 – ‘Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic… view more  Credit: Courtesy of VHIO Barcelona, Spain, 6 July 2019 – Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in…

Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations

WellnessLeave a comment

IMAGE: The trial results will be reported at the ESMO World Congress on Gastrointestinal Cancer 2019 by principal investigator Scott Kopetz, M.D., associate professor of Gastrointestinal Medical Oncology. view more  Credit: MD Anderson Cancer Center BARCELONA — The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal…